ALG Manousakis Law Firm has been ranked in the Legal 500 EMEA 2026 guide.
The firm is recognized in the following practice areas:
Commercial, Corporate and M&A (Tier 4)
ALG commercial team excels in handling M&As, shareholder disputes and corporate restructuring, as well as negotiating high value commercial (distribution, licensing, wholesaler) agreements, managing product commercialisation and ensuring regulatory adherence through structuring manufacturing deals for its clients.
EU and Competition (Tier 4)
The firm’s competition practice mainly involves assessment of vertical agreements, evaluation of parallel exports and relevant regulatory obligations and handling of investigations and researches of Competition Commissions. Pharmaceutical and medical device regulation advice is in the core of EU law practice. Main areas are clinical trials, marketing authorizations, CE marking, compliance rules for interactions with stakeholders and structuring policies for EU commercialization of products.
TMT (Tier 4)
ALG team leads complex AI and governance projects, acts as Data Protection Officer for multinational groups, and implements data privacy and compliance programs aligned with global regulatory requirements.
What makes this recognition particularly meaningful is the feedback from our clients, who highlight the combination of a “high level of expertise and pragmatism that creates a dynamic and feels more like teamwork than a traditional consultancy relationship” as well as our “strong knowledge of the industry, business-friendly approach, and problem-solving attitude” and “speed and quality of work”.
This recognition reflects our team’s continued commitment to delivering high-quality legal services and supporting leading international clients, particularly in the life sciences, pharmaceutical and technology sectors.
We are especially grateful to our clients for their trust and collaboration, and to the Legal 500 research team for this acknowledgement.
